Muscular Dystrophy Association Celebrates FDA Approval of ZILBRYSQ® zilucoplan for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients
18 oct. 2023 14h36 HE
|
Muscular Dystrophy Association
New York, Oct. 18, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of ZILBRYSQ® zilucoplan for the treatment of...
Muscular Dystrophy Association Celebrates FDA Approval of Amicus Therapeutics’ Pombiliti + Opfolda for Treatment of Pompe Disease
28 sept. 2023 17h00 HE
|
Muscular Dystrophy Association
New York, Sept. 28, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of Pombiliti™ (cipaglucosidase alfa-atga) +...
Muscular Dystrophy Association Announces Research Grants Totaling $8.4 Million
13 sept. 2023 09h00 HE
|
Muscular Dystrophy Association
New York, Sept. 13, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today the awarding of 37 new grants with a total funding commitment of $8.4 million toward...
Muscular Dystrophy Association Kicks Off 30 Days of Strength Campaign for National Muscular Dystrophy Awareness Month in September
28 août 2023 09h00 HE
|
Muscular Dystrophy Association
New York, Aug. 28, 2023 (GLOBE NEWSWIRE) -- September marks the Muscular Dystrophy Association’s (MDA) kick-off of "National Muscular Dystrophy Awareness Month," to raise awareness and critical...
Muscular Dystrophy Association International Association of Fire Fighters Launch 420 Fill the Boot Fundraisers in Cities Across America Labor Day Weekend for the Muscular Dystrophy Association
21 août 2023 13h01 HE
|
Muscular Dystrophy Association
New York, Aug. 21, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) in partnership with the International Association of Fire Fighters (IAFF) today kick off more than 420 Fill the...
Registration Now Open for 2024 MDA Clinical & Scientific Conference, to Showcase Cutting Edge Research Advancements and Clinical Achievements in Neuromuscular Disease
09 août 2023 10h35 HE
|
Muscular Dystrophy Association
New York, Aug. 09, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA), convener of the largest worldwide gathering of the neuromuscular disease community, announced today that...
Muscular Dystrophy Association Celebrates FDA Approval of UCB’s RYSTIGGO for the Treatment of Generalized Myasthenia Gravis
27 juin 2023 17h18 HE
|
Muscular Dystrophy Association
New York, June 27, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of RYSTIGGO (rozanolixizumab-noli) for the...
Muscular Dystrophy Association Celebrates FDA Approval of Sarepta Therapeutics’ ELEVIDYS for Treatment of Duchenne Muscular Dystrophy
22 juin 2023 15h31 HE
|
Muscular Dystrophy Association
New York, June 22, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) accelerated approval of ELEVIDYS (delandistrogene...
Muscular Dystrophy Association Celebrates FDA Approval of argenx’s Vyvgart Hytrulo Injection for Treatment of Generalized Myasthenia Gravis
20 juin 2023 21h29 HE
|
Muscular Dystrophy Association
New York, June 20, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of subcutaneous (SC) Vyvgart Hytrulo (efgartigimod...
CureDuchenne, Muscular Dystrophy Association, and Parent Project Muscular Dystrophy Announce Collaborative Project to Focus on Re-Dosing Gene Therapy in Duchenne Muscular Dystrophy
15 juin 2023 14h43 HE
|
Muscular Dystrophy Association
New York, June 15, 2023 (GLOBE NEWSWIRE) -- June 15, 2023 -- CureDuchenne, Muscular Dystrophy Association (MDA), and Parent Project Muscular Dystrophy (PPMD), today announced a collaborative...